Trial Profile
Phase I study of ABT-510 in combination with bevacizumab in advanced solid tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Nov 2014
Price :
$35
*
At a glance
- Drugs ABT 510 (Primary) ; Bevacizumab (Primary)
- Indications Breast cancer; Head and neck cancer; Malignant melanoma; Renal cancer; Sarcoma; Solid tumours
- Focus Adverse reactions
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00586092).
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00586092).
- 13 Dec 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.